Enteric dysbiosis and fecal calprotectin expression in premature infants. by Ho, Thao TB et al.
UC San Diego
UC San Diego Previously Published Works
Title
Enteric dysbiosis and fecal calprotectin expression in premature infants.
Permalink
https://escholarship.org/uc/item/5k7124c8
Journal
Pediatric research, 85(3)
ISSN
0031-3998
Authors
Ho, Thao TB
Groer, Maureen W
Kane, Bradley
et al.
Publication Date
2019-02-01
DOI
10.1038/s41390-018-0254-y
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Enteric Dysbiosis and Fecal Calprotectin Expression in 
Premature Infants
Thao T. B. Ho1, Maureen W. Groer1,2, Bradley Kane2, Alyson L. Yee3,4,5, Benjamin A. 
Torres1, Jack A. Gilbert4,5,6, and Akhil Maheshwari7,*
1Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, 
Florida. 2College of Nursing, University of South Florida, Tampa, Florida. 3Interdisciplinary 
Scientist Training Program, University of Chicago, Chicago, Illinois. 4Microbiome Center, 
University of Chicago, Chicago, Illinois. 5Department of Surgery, University of Chicago, Chicago, 
Illinois. 6Argonne National Laboratory, Chicago, Illinois. 7Department of Pediatrics, Johns Hopkins 
University School of Medicine, Baltimore, Maryland.
Abstract
Background: Premature infants often develop enteric dysbiosis with a preponderance of 
Gammaproteobacteria, which has been related to adverse clinical outcomes. We investigated the 
relationship between increasing fecal Gammaproteobacteria and mucosal inflammation, measured 
by fecal calprotectin (FC).
Methods: Stool samples were collected from very-low-birth weight (VLBW) infants at ≤2, 3, 
and 4 weeks’ postnatal age. Fecal microbiome was surveyed using PCR-amplification of the V4 
region of 16S rRNA, and FC was measured by enzyme immunoassay.
Results: We enrolled 45 VLBW infants (gestation 27.9±2.2 weeks, birth weight 1126±208 g) 
and obtained stool samples at 9.9±3, 20.7±4.1, and 29.4±4.9 days. FC was positively correlated 
with the genus Klebsiella (r = 0.207, p = 0.034) and its dominant amplicon sequence variant (r = 
0.290, p = 0.003) but not with the relative abundance of total Gammaproteobacteria. Klebsiella 
colonized the gut in two distinct patterns: some infants started with low Klebsiella abundance and 
gained these bacteria over time, whereas others began with very high Klebsiella abundance.
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Conclusion: In premature infants, FC correlated with relative abundance of a specific 
pathobiont, Klebsiella, and not with that of the class Gammaproteobacteria. These findings 
indicate a need to define dysbiosis at genera or higher levels of resolution.
BACKGROUND
In healthy, full-term neonates, the intestine is seeded by microbial inocula received from the 
birth canal, maternal skin, and milk, and the gut microbiome is dominated by Gram-positive 
Firmicutes such as Staphylococcus, Propionibacterium, Bifidobacterium, and Lactobacillus 
(1). Increasing pre-clinical and epidemiological information now acknowledges the positive 
influence of these bacteria on mucosal homeostasis, immunity, nutrient absorption, and 
energy regulation in the neonatal intestine (2,3). In contrast, in preterm infants, the intestinal 
microbiome may develop very differently (4). In these infants, the hospital microflora may 
contribute more to the gut microbiome, whereas the maternal influence may be curtailed due 
to shortened labor or a Cesarean birth, limited physical contact with the mother, and periods 
of enteral fasting. There may be additional selection pressures from broad-spectrum 
antibiotics, indwelling tubes and catheters, intestinal dysmotility, and immaturity of barriers 
such as gastric acid, secretory IgA, and mucus (1). Not surprisingly, many preterm infants 
develop an enteric dysbiosis with a preponderance of Gram-negative bacteria of the class 
Gammaproteobacteria and its constituent families Enterobacteriaceae, Vibrionaceae, and 
Pseudomonadaceae (5–8). Emerging epidemiological data link such dysbiosis with adverse 
outcomes such as necrotizing enterocolitis, cholestasis, and developmental delay (4,6,7,9), 
but the mechanism(s) by which Gammaproteobacteria present in the bowel lumen may 
evoke inflammatory responses are not well-understood. Intestinal epithelium and many 
resident immune cell lineages are normally tolerant of Gram-negative bacteria (10), and 
further study is needed to ascertain if dysbiosis secondary to a gammaproteobacterial bloom 
may induce mucosal inflammation when the relative abundance of Gammaproteobacteria 
exceeds a critical threshold, or is associated with an increase in specific pathobionts in this 
class of bacteria.
In this prospective observational study, we investigated the relationship between fecal 
Gammaproteobacteria and mucosal inflammation in premature infants. We used fecal 
calprotectin (FC), which is derived from neutrophils and inflammatory macrophages present 
in the mucosa, as the inflammatory marker (11). Preterm infants tend to have greater 
variability in FC expression than older children and adults, but several studies now show FC 
to be a useful marker of intestinal inflammation and necrotizing enterocolitis (NEC) when 
cut-off values between 200–300 μg/g of stool were used (11–14). We hypothesized that that 
FC increases in preterm infants as a function of the relative abundance of 
Gammaproteobacteria in stool. To test this hypothesis, we recorded demographic and 
clinical information from a cohort of very-low-birth weight (VLBW) infants, surveyed their 
fecal microbiome, and measured FC at serial time-points during the neonatal period.
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METHODS:
Demographic and clinical information:
This study was performed at University of South Florida and the affiliated Tampa General 
Hospital (TGH) under appropriate oversight from the Institutional Review Boards. The 
neonatal intensive care unit (NICU) at TGH is an academic regional referral center with a 
single-patient room floor plan. All eligible VLBW infants were enrolled during the period 
May 2012 to December 2013; inclusion criteria included birth weight <1500 g, availability 
of a stool sample in the first 2 weeks after birth, and parental informed consent. Infants with 
major congenital anomalies or lethal chromosomal disorders were excluded. Three stool 
samples were obtained from each infant at ≤2, 3rd, and the 4th week after birth and stored at 
−80°C until the time of analysis. Biological samples were handled under uniform conditions 
per accepted guidelines (biospecimen reporting for improved study quality). (15)
Fecal DNA amplification:
Total DNA was extracted from 100–250 mg of stool (MoBio PowerFecal DNA kit, Qiagen, 
Carlsbad, CA) and V4 region of bacterial 16S rRNA gene was amplified by polymerase 
chain reaction with modified 515F and 806R primers (16). Amplicons were sequenced 
according to Illumina MiSeq protocol (Illumina, San Diego, CA) to generate about 15,000 
of 250 base-pair paired-end reads per sample.
Metagenomic analysis:
Demultiplexed DNA sequences were first uploaded to the CLC Biomedical Workbench 3.5.3 
(Qiagen) and analyzed for bacterial classifications to genus level. Bacterial Operational 
Taxonomic Units (OTUs) were mapped to the Greengenes v13.8 reference database at 97% 
similarity, and their relative abundances (%) were computed. Diversity within samples 
(alpha diversity) were measured and represented by the number of OTUs, phylodiversity, 
Chao 1, Simpson, and Shannon indices. To improve taxonomic resolution, we next used the 
Divisive Amplicon De-noising Algorithm 2 (DADA2) to characterize bacterial OTUs to 
amplicon sequence variants (ASVs). This 2-step analysis provided information on OTUs to 
allow comparison with existing studies of the preterm microbiome (5–7,17–19), and allowed 
validation of our results with the DADA2 pipeline that relies on a different, model-based 
approach to minimize amplicon errors.
Changes in the abundance of individual OTUs were investigated using Gneiss (balance tree) 
analysis (20). Due to the compositional nature of 16S rRNA gene sequence data, the relative 
(proportional) abundance of a taxon could be altered either due to a change in its own 
numbers or due to a shift in the relative abundance of other taxa. Balance tree analysis 
circumvents this problem by leveraging the correlation between co-occurring taxa to infer 
meaningful properties of sub-communities, rather than individual taxa.
Fecal Calprotectin (FC) measurements:
We used a commercially-available enzyme immunoassay (PhiCal, Genova Diagnostics, 
Ashville, NC). The linear range of measurement for this assay is 25–2500 μg/g stool.
Ho et al. Page 3
Pediatr Res. Author manuscript; available in PMC 2019 June 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Statistical Analysis:
Clinical and demographic data were analyzed using SPSS 25 (IBM, Armonk, NY). Scalar 
variables were compared by Friedman’s test for repeated measures or the Mann-Whitney U 
test, and categorical variables by Fisher’s exact test. Linear mixed-effects models were used 
to identify determinants of FC and Klebsiella abundance. Small-for-gestational age (SGA), 
ethnicity, vaginal birth, antenatal steroids, magnesium sulfate, chorioamnionitis, gender, 
multiple births, postnatal age, enteral feedings (binary), respiratory distress syndrome, 
patency of ductus arteriosus, sepsis, red blood cell transfusions (binary), and Klebsiella 
abundance were defined as fixed effects as all possible levels of the variable were 
represented in the cohort. Maternal body-mass index (BMI), birth weight, gestation, 
postmenstrual age at stool collection, duration of ruptured membranes, and days of antibiotic 
treatment were defined as random effects. Mixed-effects procedures were performed using 
the maximum likelihood method and an autoregressive covariance matrix (with 
heterogeneous variances) as the dependent variables were anticipated to diverge with time. 
Best-fitting models were identified by −2 log likelihood, Akaike’s information criterion, and 
Schwarz’s Bayesian criterion. Important independent variables were shortlisted using 
bootstrap bagging, where a bootstrap dataset was constructed by not sampling a third of all 
subjects and replacing these by an equal number of duplicated samples. The bootstrap 
sample was analyzed by logistic regression with entry criterion of p<0.2. To avoid model 
overfitting, multivariable analyses were limited to biologically plausible associations, to 
main effects for baseline measures, and time-dependent covariates for longitudinal 
measures.
We also performed linear regression to identify predictors of FC at different time-points of 
stool collection. Independent variables were tested with entry at p<0.2 and acceptance at 
p<0.05, first using a onestep forced entry and then ‘stepwise’ in the sequence of appearance 
during perinatal period. In addition to the variables listed above, duration of iron therapy was 
also tested. To identify highly-correlated variables, multicollinearity diagnostics (tolerance 
values <0.2, variance inflation factors >10) were reviewed. Independence of variables was 
confirmed by the Durbin-Watson statistic (acceptable range 1.5–2.5). Scatterplots of 
standardized residuals vs. standardized predicted values were evaluated for homoscedasticity 
and non-linearity. Normality of residuals was confirmed by evaluation of histograms. To 
determine Klebsiella abundance levels associated with elevated FC, we computed receiver-
operating characteristics (ROCs) by plotting sensitivity vs. 1-specificity and identified ‘cut-
off’ abundance values at the highest sum of sensitivity and specificity (Youden’s J statistic). 
Statistical tests were two-tailed and considered significant at p<0.05.
RESULTS
Demographic and clinical information:
We enrolled 45 eligible VLBW infants admitted to our NICU between May 2012 and 
December 2013. The clinical characteristics of this cohort have been described in part, 
elsewhere (21). These infants were born at a gestation (mean ± standard deviation, SD) of 
27.9±2.2 weeks, with birth weight 1126±208 g. Their clinical characteristics are 
summarized in table 1 of our previous publication (22).
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Fecal calprotectin:
Stool samples for the ≤2, 3rd, and 4th week time-points were collected at postnatal age (mean 
± SD) 9.9±3, 20.7±4.1, and 29.4±4.9 days; and post-menstrual age 29.8±2.3, 31.2±1.9, and 
32.6±1.9 weeks, respectively. FC levels remained stable over time [median (interquartile 
range/IQR): 161 (101–277), 187 (132–306), and 152 (102–311) μg/g stool in ≤2, 3rd and 4th 
week, respectively; Friedman’s test; difference not significant (N.S.)].
Fecal microbiome:
A total of 2,017,727 reads was obtained (mean ± SD 15,285±7,139 sequences per sample). 
The alpha-diversity metrics (number of OTUs, phylodiversity, and Shannon, Chao1, and 
Simpson indices) increased with postnatal age (Figure 1). The relative abundance of 
Proteobacteria increased over time, comprising 46% (median; IQR = 0–90%) of all reads at 
≤2 weeks, 83.5% (54.8–93.3%) in the 3rd, and 77% (57–88.3%) in the 4th week (p < 0.001). 
Gammaproteobacteria accounted for 42.5% (0–90%) of all reads in ≤2 weeks, 69.7% (29.9–
86.9%) in the 3rd, and 75.5% (54.5–86%) in the 4th week stool samples (p<0.001). 
Klebsiella were the dominant gammaproteobacterial genus: median (IQR) 44% (2–98%), 
85% (0–98%), and 78.5% (11.3–97.5%) in the <2, 3rd, and 4th week stool samples, 
respectively as summarized in supplemental table 3 of our previous publication.22 An ASV 
of Klebsiella accounted for nearly a third of all reads in weeks 3–4 [median 0.18% (IQR 0–
65%) at ≤2 weeks, 24.6% (0–80%) in the 3rd, and 26.2% (0.1–66.9%) in the 4th week 
(N.S.)].
Predictors of Fecal calprotectin:
In bivariate analyses, FC was positively correlated with birth weight (Spearman’s r = 0.337, 
p<0.001), particularly during the 3rd (r = 0.417, p = 0.009) and 4th weeks (r = 0.501, p = 
0.005), but not with gestation or post-menstrual age. There was no correlation between FC 
and the relative abundance of Proteobacteria or its constituent Gammaproteobacteria (or the 
other major phyla, Firmicutes and Actinobacteria) in stool. Interestingly, FC was positively 
correlated with the genus Klebsiella (r = 0.207, p = 0.034) but not with other 
Gammaproteobacteria (Table 1). FC was also correlated with the Klebsiella ASV described 
above (r = 0.290, p = 0.003).
We used mixed-effects models to identify predictors of FC across the repeated 
measurements. The best-fitting, parsimonious model (Table 2) showed positive associations 
with vaginal birth (F = 83.29, p < 0.001), Hispanic ethnicity (F = 7.89, p = 0.006), and 
Klebsiella abundance (F = 4.54, p = 0.035). The association with the dominant ASV of 
Klebsiella was even stronger (F = 7.37, p = 0.008). We also performed linear regression to 
identify determinants of FC at different time-points of stool collection. At ≤2 weeks, the best 
fitting model (r2 = 0.68, F = 35.76, p<0.001) showed positive effects of maternal BMI (B = 
6.08, t = 5.72, p<0.001) and confirmed the association with vaginal birth (B = 157.62, t = 
2.73, p = 0.01). During the 3rd week (r2 = 0.8, F = 40.77, p <0.001), FC was associated with 
birth weight (B = 0.3, t = 7.29, p<0.001) and Hispanic ethnicity (B = 256.19, t = 3.52, p = 
0.001), but days of iron supplementation had a negative impact (B = −20.8, t = −3.39, p = 
0.002). In the 4th week regression model (r2 = 0.61, F = 18.96, p <0.001), the associations 
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with birth weight (B = 0.2, t = 4.93, p<0.001) and Hispanic ethnicity (B = 334.69, t = 2.08, p 
= 0.048) were still evident.
We also computed receiver-operating characteristics (ROCs) of Klebsiella abundance to 
identify a cut-off value that predicted high FC levels similar to those recorded in infants with 
mucosal inflammation (>280 μg/g stool) 12. Klebsiella abundance ≥ 83% predicted FC>280 
μg/g with 72% sensitivity and 60% specificity (area under the curve, AUC = 0.646, p = 
0.028; Figure 2a). In the 3rd week, Klebsiella abundance ≥ 76% predicted elevated FC with 
89% sensitivity and 57% specificity (AUC = 0.722, p = 0.047; Figure 2b).
Predictors of the relative abundance of Klebsiella in stool:
Similar to the observed associations of FC, Klebsiella abundance was also related in mixed-
effects models to vaginal birth (F = 5.68, p = 0.015) and Hispanic ethnicity (F = 124.33, 
p<0.001). The dominant ASV of Klebsiella was also affected by the same clinical 
antecedents, vaginal birth (F = 13.46, p<0.001) and Hispanic ethnicity (F = 57.81, p<0.001).
Clustering of infants based on Klebsiella abundance at ≤ 2 weeks:
To investigate whether the variability (range 0–98%) in Klebsiella abundance we observed in 
the ≤2-week stool samples indicated the presence of more than one distinct subgroups of 
infants in our cohort, we used agglomerative hierarchical and K-means clustering 
procedures. These analyses revealed 2 subgroups with distinct cluster centers (13% vs. 94% 
in clusters 1 and 2, respectively; F = 370.83, p <0.001; analysis of variance; Figure 2). In 
cluster 1 (n = 23), the relative abundance of Klebsiella (and its dominant ASV) started at low 
levels and increased over time (Friedman test, p = 0.009 and 0.021 for Klebsiella and its 
dominant ASV, respectively). In contrast, Klebsiella dominated the intestinal microbiome in 
cluster 2 (n = 21). There was minimal loss of Klebsiella abundance over time (p = 0.018; 
Table 3) but the Klebsiella ASV remained stable. Gneiss (balance tree analysis) 20 confirmed 
that these cluster differences in Klebsiella abundance were significant and not merely due to 
decreased abundance of other taxa (Figure 3). In support of these data, the accumulative 
ratios of major bacterial families vs. Klebsiella (Figure 4) decreased over time in cluster 1, 
consistent with the acquisition of Klebsiella. Cluster 2 started with and maintained low 
ratios, indicating persistently high levels of Klebsiella compared to other taxa.
The two clusters were similar in birth weight and gestational age. Cluster 1 experienced a 
shorter duration of maternal ruptured membranes but had more days on antibiotics. There 
was no difference in major neonatal morbidities, days to full enteral feeds (150 mL/kg), days 
on positive pressure respiratory support, Z-scores for weight on postnatal day 28 and at 36 
weeks’ post-menstrual age (based on Fenton growth charts), and length of hospital stay. A 
summary of the clinical characteristics of the two clusters in Table 4.
In mixed-effects models, Klebsiella abundance in cluster 1 increased with postnatal age (F = 
5.0, p = 0.028) and antenatal steroids (F = 5.8, p = 0.019), whereas antenatal magnesium 
sulfate (F = 8.5, p = 0.005) and chorioamniotitis (F=5.2, p = 0.026) had a negative effect. 
The association with antenatal steroids was also detectable in cluster 2 (F=5.3, p = 0.025). In 
cluster 1, Klebsiella ASV also increased with postnatal age (F = 5.8, p = 0.018), and 
decreased with antenatal magnesium sulfate (F = 8.1, p = 0.006) and chorioamnionitis (F = 
Ho et al. Page 6
Pediatr Res. Author manuscript; available in PMC 2019 June 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4.6, p = 0.035). In cluster 2, Klebsiella ASV was associated with vaginal delivery (F = 6.6, p 
= 0.013).
Cluster 1 had lower FC levels overall than cluster 2 [median (IQR) 148 (99–215) in cluster 1 
vs. 226 (112–362) μg/g in cluster 2, respectively; p = 0.011). FC values were the highest in 
cluster 2 at ≤ 2 weeks [median (IQR) 243 (121–331) μg/g in cluster 2 vs. 148 (83–199) in 
cluster 1; p = 0.04]. Antenatal magnesium sulfate had a negative effect on FC in cluster 1 (F 
= 15.0, p<0.001), but a positive effect was seen in cluster 2 (F=5.8, p=0.02). Antenatal 
steroids had a negative effect on FC in cluster 2 (F = 6.0, p = 0.018).
DISCUSSION
We present a detailed investigation of the relationship between fecal colonization with 
Gammaproteobacteria in VLBW infants and FC, a biomarker of gut mucosal inflammation. 
In our cohort, Gammaproteobacteria abundance did not affect FC expression. Instead, we 
found FC to be associated specifically with the presence of Klebsiella, and even more 
strongly, with a particular ASV within this genus. We observed two distinct paths to enteric 
colonization with Klebsiella: infants in cluster 1 began with very low abundance and gained 
modest levels of these bacteria over time, whereas the gut microbiome in cluster 2 was 
completely dominated by Klebsiella. High FC in cluster 2 infants indicated ongoing host-
microbial interaction and a measureable innate immune response to these luminal bacteria. 
Importantly, Klebsiella abundance ≥ 83% predicted elevated FC levels similar to those seen 
during intestinal inflammation and NEC. To our knowledge, this is the first study to evaluate 
enteric dysbiosis in preterm infants in the context of the host inflammatory response.
The association of FC with fecal Klebsiella in our study raises several scientific questions. 
First, our findings call into question the practice of evaluating Gammaproteobacteria en bloc 
in the preterm microbiome. In recent years, several studies show that premature infants with 
a diagnosis of NEC had developed enteric dysbiosis with increased Gammaproteobacteria 
for several days to weeks antedating NEC onset (5–8). However, the lack of correlation 
between Gammaproteobacteria abundance and FC in our cohort suggests that 
Gammaproteobacteria may be too diverse a group to consistently exert a net inflammatory 
effect, and indicates a need for defining dysbiosis at higher levels of resolution. Second, we 
recorded highest FC levels in cluster 2 during the early neonatal period, when Klebsiella 
dominated in a setting of low alpha-diversity. These findings are important in efforts to 
develop a clinically-relevant definition for dysbiosis; further study is needed to clarify 
whether the relative abundance of a pathobiont is relevant in isolation, or if it needs to be 
interpreted in conjunction with the diversity indices. Third, further study is needed to 
determine whether the early appearance of Klebsiella in some premature infants was unique 
to our center or if it represents a universal phenomenon in Page 13 of 36 these patients. The 
inflammatory effects of Klebsiella in the intestine are plausible, considering the presence of 
potent virulence factors such as cell wall components and enterotoxins (23,24). Klebsiella 
are recognized intestinal pathogens of preterm and term neonates, having been identified in 
diarrhea, ecchymotic colitis, bacteremia during NEC and short-bowel syndrome, and even in 
NEC outbreaks (25–29). The correlation between fecal Klebsiella and elevated FC has been 
previously noted in infantile colic (30). Early colonization with Klebsiella has been noted in 
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other preterm cohorts (6,8), but the possibility of finding distinct inflammation-driving 
pathobiont(s) at other centers cannot be excluded. In our own cohort, the correlation 
between FC and Klebsiella was relatively modest (r = 0.21), and when clustering was 
attempted based on FC, subgroup differences in Klebsiella did not reach significance. 
Finally, even though current evidence supports dysbiosis as an inflammatory stimulus, we 
need to acknowledge that a reciprocal effect, where pre-existing inflammation in the 
intestinal mucosa may promote a Gammaproteobacterial bloom, also warrants exploration.
Calprotectin is a 24 kDa dimer of the calcium-binding proteins calgranulin A/S100A8 and 
calgranulin B/S100A9, expressed in neutrophils and inflammatory monocytes (11–14). FC 
has found wide acceptance as a non-invasive marker of gut mucosal inflammation because it 
is strongly correlated with leukocyte infiltration in the mucosa, is stable in stool at room 
temperature for several days, and is easy to measure (31). Premature infants tend to have 
higher and more variable FC than adults, but higher cut-off values such as 280 μg/g stool 
have been correlated with intestinal inflammation and NEC (11–14). Treatment with non-
steroidal anti-inflammatory drugs (NSAIDs) can increase FC 32, but in our cohort, the FC 
levels in the 2 infants who received indomethacin for treatment of PDA were not higher than 
the rest.
Vaginal birth was an important determinant of the relative abundance of Klebsiella (and the 
dominant Klebsiella) in stool and of FC expression. These findings suggest that Klebsiella 
were likely acquired via vertical, mother-to-infant transmission. The near-total dominance of 
the gut microbiome in some infants (cluster 2) within the first 2 weeks after birth also lends 
credence to this possibility. However, the source of these bacteria is unclear. During 
pregnancy, the vaginal microbiome is dominated by Firmicutes (33,34). In women with 
vaginal dysbiosis, pathobionts such as Prevotella, Sneathia, Atopobium, Mycoplasma, and 
Gardnerella can be identified, but Klebsiella are infrequent (34). Perinatal exposure to 
maternal enteric flora during vaginal birth and to the microbiome of human milk, which 
contain Klebsiella (35,36), are two possible sources. Increased maternal BMI and diabetes 
have been previously associated with enrichment of Enterobacteriaceae, including 
Klebsiella, in both maternal and neonatal gut microbiome (37). Unfortunately, we are unable 
to investigate these findings further because we did not collect maternal samples in the 
present study.
We found higher Klebsiella abundance and FC in Hispanic infants. Although racial/ethnic 
differences in the enteric microbiome are possible (38), the type of feedings could have had 
a confounding influence: 8/9 (88.8%) Hispanic infants received only human milk vs. 17/36 
(47.2%) infants of other ethnic groups (p = 0.03). The correlation between birth weight and 
FC likely reflects the maturational expansion of the mucosal leukocyte populations, and 
thus, the improving ability of the host to launch an innate immune response. Associations 
with antenatal steroids and magnesium sulfate may be more difficult to explain; steroids 
could influence the host-microbial cross-talk through altered leukocyte function and 
cytokine expression, and epigenetic changes in the mucosa (39). Perinatal exposure to 
magnesium sulfate can also alter gut motility and some immune responses (40), but the 
effects on fecal microbiome are unclear.
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In conclusion, we show that FC expression in VLBW infants was specifically associated 
with the genus Klebsiella and a dominant ASV mapping to this genus, but not with the 
relative abundance of all Gammaproteobacteria in stool. These findings are important in the 
quest to develop a clinically-relevant definition of enteric dysbiosis in premature infants. 
Major strengths of our study are repeated measurements of the gut microbiome and FC, and 
the single-patient room floor-plan of our NICU, which now represents the layout in most of 
the newer NICUs in the United States. There are important limitations, such as the limited 
sample size and the single-center design. In our cohort, Klebsiella abundance affected FC 
but not the clinical outcome; we had only a single patient with NEC, which made it difficult 
to analyze the clinical effects of abnormal microbial colonization and mucosal inflammation. 
Further study is needed in a larger, multicenter Page 15 of 36 cohort to validate our findings, 
particularly to confirm the dichotomous development of the gut microbiome and the 
importance of Klebsiella as a leading pathobiont in preterm infants.
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Figure 1: Longitudinal change in alpha-diversity indices.
Boxplots (median and 95% confidence interval) summarize number of OTUs, Chao 1, 
Simpson, Shannon, and phylodiversity indices. (**) and (***) indicate p<0.01 and p<0.001 
respectively in comparison to the ≤2 weeks samples.
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Figure 2: Fecal Klebsiella predict FC expression:
(a) Relative abundance of Klebsiella ≥ 83% in stool predicted high FC (>280 μg/g of stool) 
with 72% sensitivity and 60% specificity (area under curve, AUC = 0.646); (b) During the 
3rd postnatal week, Klebsiella abundance ≥76% predicted high FC with 89% sensitivity and 
57% specificity (AUC = 0.722).
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Figure 3: 
Proportion plot based on balance tree calculation shows shifts in major genera between the 
two clusters.
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Figure 4: Temporal change in bacterial abundances at family level relative to Klebsiella in the 
two clusters.
Top: Boxplots summarize accumulative ratios of major bacterial families vs. Klebsiella 
(natural log-transformed, Ln) in the two patient clusters. Bottom: Bar diagrams summarize 
the distribution of major bacterial taxa at the family level in the numerator and the 
denominator.
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Figure 5: Longitudinal change in fecal Klebsiella abundance.
Scatter dot plots summarize fecal Klebsiella abundance over time. Open and solid circles 
indicate the two sub-groups of infants identified in our cohort by K-means clustering 
analysis of fecal Klebsiella abundance at ≤2 weeks. Cluster 1 (23 infants, open circles) 
started with low Klebsiella abundance and gained these bacteria over time (Friedman test, p 
= 0.009). Cluster 2 (21 infants, solid circles) showed high Klebsiella abundance with minor 
attrition in weeks 3 and 4 (p = 0.018).
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Table 1.
Bivariate correlation between FC and the relative abundance of major genera in the class 
Gammaproteobacteria
Genus r p-value
Klebsiella 0.207 0.034
Haemophilus −0.023 0.820
Proteus −0.099 0.316
Acinetobacter 0.089 0.365
Vibrio −0.142 0.148
Pseudomonas 0.002 0.985
Enhydrobacter −0.040 0.685
Salmonella −0.084 0.392
Microbulbifer −0.103 0.297
Trabulsiella 0.176 0.073
Arenimonas 0.024 0.804
Photobacterium −0.041 0.680
Cardiobacterium −0.041 0.680
Serratia 0.019 0.845
Stenotrophomonas −0.064 0.514
Morganella −0.007 0.946
Erwinia −0.057 0.566
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Table 2.
Predictors of FC
Parameter Estimate Std. Error df t p-value
95% Confidence Interval
Lower Bound Upper Bound
Vaginal birth 348.220 67.270 105.000 5.176 0.000 214.836 481.604
Non-Hispanic ethnicity −127.186 51.705 105.000 −2.460 0.016 −229.707 −24.664
Relative abundance of Klebsiella 0.932 0.437 105.000 2.132 0.035 0.065 1.799
Female gender −61.289 36.944 105.000 −1.659 0.100 −134.542 11.964
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Table 3:
Klebsiella abundances in stool and FC over time, by cluster
Cluster 1 Cluster 2
Time of 
stool 
collection
Klebsiella (%) 
[median 
(IQR)]
Klebsiella ASV 
(%) [median 
(IQR)]
FC (μg/g stool) 
[median(IQR)]
Klebsiella (%) 
[median (IQR)]
Klebsiella ASV (%) 
[median (IQR)]
FC (μg/g stool) 
[median (IQR)]
≤2 weeks 5 (0–30) 0 (0–0.1) 148 (83–199) 98 (94.5–99) 66.4 (0.7–94) 243 (121–331)
3rd week 19.5 (0–86) 0.1 (0–36.6) 162 (123–210) 98 (70–98.8) 80.7 (15.3–89.4) 227 (142–417)
4th week 21 (0–74.8) 0.3 (0–26.2) 134 (79–285) 96 (80–98) 59.6 (29.4–75.4) 163 (102–436)
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Table 4:
Perinatal and Neonatal Clinical Characteristics of the Two Clusters
Characteristic Cluster 1 N=23 Cluster 2 N=21 p values
Gestational age (weeks, mean ± SD) 28±2 28±2 0.281
Birth weight, grams, (mean, SD) 1099±220 1144±187 0.211
Male 12 (52.2%) 8 (38.1%) 0.382
Hispanic ethnicity 4 (17.4%) 5 (23.8%) 0.716
Race 0.302
    Black 12 (52.2%) 7 (33.3%)
    White 11 (47.8%) 13 (61.9%)
Antenatal medications
    Steroids 20 (87%) 19 (90.5%) 1.000
    Magnesium 17 (73.9%) 17 (81%) 0.724
Vaginal birth 4 (17.4%) 7 (33.3%) 0.303
Multiple birth 6 (26.1%) 1 (4.8%) 0.097
Ruptured membrane (hours, mean ± SD) 17±64 65±173 0.038
Chorioamnionitis 15 (65.2%) 10 (47.6%) 0.521
Maternal hypertension 6 (26.1%) 7 (33.3%) 0.744
Small for gestational age 2 (8.7%) 1 (4.8%) 1.000
Respiratory distress syndrome 14 (60.9%) 26 (57.8%) 0.762
Oxygen on day 28 6 (26.1%) 4 (19.0%) 0.724
Oxygen on day 36 1 (8.7%) 1 (4.8%) 1.000
Significant patent ductus arteriosus 2 (13.3%) 3 (14.3%) 0.658
Indomethacin 0 2 (9.5%) 0.222
Patent ductus arteriosus ligation 1 (2.2%) 0 1.000
Retinopathy of prematurity 2 (8.7%) 4 (19%) 0.403
Intraventricular hemorrhage 1 (4.3%) 4 (19%) 0.176
Necrotizing enterocolitis 1 (4.3%) 0 1.000
Days on antibiotics, (mean, SD) 5.3 (6.0) 3.7 (2.5) 0.045
Positive blood culture 3 (13.0%) 2 (9.5%) 1.000
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Characteristic Cluster 1 N=23 Cluster 2 N=21 p values
Packed red blood cell transfusion 7 (30.4%) 8 (38.1%) 0.752
Feeding type 0.936
    Maternal breast milk only 12 (52.2%) 12 (57.1%)
    Formula only 1 (4.3%) 1 (4.8%)
    Mixed feeding types 10 (43.5%) 8 (38.1%)
Days to full enteral feeds; median (range) 11 (6–19) 11 (5–17) 0.623
Z-score for weight, postnatal day 28; median (range) −0.89 (−3.72 to 1.14) −0.52 (−2.56 to 1.71) 0.301
Z-score for weight, post-menstrual age 36 weeks; median (range) −0.81 (−3.72 to 1.09) −0.41 (−2.39 to 1.56) 0.459
Days on respiratory support 34 (0–92) 42 (0–68) 0.689
Discharge weight <10th percentile 5 (21.7%) 6 (28.6%) 0.732
Length of stay (days, mean ± SD) 71±34 64±21 0.163
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